Lataa...
Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety—Particularities in the Context of COVID-19
Background: clozapine (CLZ) use is precarious due to its neurological, cardiovascular, and hematological side effects; however, it is the gold standard in therapy-resistant schizophrenia (TRS) in adults and is underused. Objective: to examine the most recent CLZ data on (a) side effects concerning (...
Tallennettuna:
| Julkaisussa: | Brain Sci |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7697202/ https://ncbi.nlm.nih.gov/pubmed/33187329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/brainsci10110840 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|